Philip S. Hyder

Array ( [id] => 17929787 [patent_doc_number] => 20220324912 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => THERAPEUTIC PEPTIDES [patent_app_type] => utility [patent_app_number] => 17/634466 [patent_app_country] => US [patent_app_date] => 2020-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35596 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17634466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17497586 [patent_doc_number] => 11286279 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-29 [patent_title] => Compositions for expanding regulatory T cells (Treg), and treating autoimmune and inflammatory diseases and conditions [patent_app_type] => utility [patent_app_number] => 16/989816 [patent_app_country] => US [patent_app_date] => 2020-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 26 [patent_no_of_words] => 20384 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16989816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17655484 [patent_doc_number] => 20220175949 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2022-06-09 [patent_title] => PEPTIDES DERIVED FROM TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 1 (TRPM1), COMPLEXES COMPRISING SUCH PEPTIDES BOUND TO MHC MOLECULES [patent_app_type] => utility [patent_app_number] => 16/988523 [patent_app_country] => US [patent_app_date] => 2020-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9787 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16988523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17655484 [patent_doc_number] => 20220175949 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2022-06-09 [patent_title] => PEPTIDES DERIVED FROM TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 1 (TRPM1), COMPLEXES COMPRISING SUCH PEPTIDES BOUND TO MHC MOLECULES [patent_app_type] => utility [patent_app_number] => 16/988523 [patent_app_country] => US [patent_app_date] => 2020-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9787 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16988523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20402256 [patent_doc_number] => 12492225 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => Melanocyte-regulating peptides [patent_app_type] => utility [patent_app_number] => 17/632463 [patent_app_country] => US [patent_app_date] => 2020-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 11426 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 536 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17632463 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17805876 [patent_doc_number] => 20220257711 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => PEPTOID-PEPTIDE HYBRID, NMEG-aCGRP, AND ITS USE IN CARDIOVASCULAR DISEASES [patent_app_type] => utility [patent_app_number] => 17/630662 [patent_app_country] => US [patent_app_date] => 2020-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12226 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17630662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621501 [patent_doc_number] => 20210040154 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => HETEROTANDEM BICYCLIC PEPTIDE COMPLEX [patent_app_type] => utility [patent_app_number] => 16/941614 [patent_app_country] => US [patent_app_date] => 2020-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16941614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403623 [patent_doc_number] => 20240287134 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => PEPTIDES FOR USE AS SENOTHERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 17/631865 [patent_app_country] => US [patent_app_date] => 2020-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7419 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17631865 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18576713 [patent_doc_number] => 11733233 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-22 [patent_title] => Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases [patent_app_type] => utility [patent_app_number] => 16/935097 [patent_app_country] => US [patent_app_date] => 2020-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 62 [patent_figures_cnt] => 85 [patent_no_of_words] => 73663 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16935097 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16468495 [patent_doc_number] => 20200370032 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => MODIFICATIONS OF PEPTIDE COMPOSITIONS TO INCREASE STABILITY AND DELIVERY EFFICIENCY [patent_app_type] => utility [patent_app_number] => 16/933749 [patent_app_country] => US [patent_app_date] => 2020-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5832 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16933749 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17988892 [patent_doc_number] => 20220354929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => PEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/622202 [patent_app_country] => US [patent_app_date] => 2020-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25098 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -52 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17622202 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17541011 [patent_doc_number] => 11306122 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-19 [patent_title] => Compositions and methods of inhibiting the binding of plasma IgG autoantibodies to serotonin 2A receptor [patent_app_type] => utility [patent_app_number] => 16/897071 [patent_app_country] => US [patent_app_date] => 2020-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 38 [patent_no_of_words] => 37655 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16897071 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18246822 [patent_doc_number] => 11603395 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-14 [patent_title] => Antitumor peptide and use thereof [patent_app_type] => utility [patent_app_number] => 16/889020 [patent_app_country] => US [patent_app_date] => 2020-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8918 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16889020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16310929 [patent_doc_number] => 20200289667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => Targeting Macrophages to Modulate Electrical Conduction in the Heart [patent_app_type] => utility [patent_app_number] => 16/889682 [patent_app_country] => US [patent_app_date] => 2020-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14577 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16889682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16312328 [patent_doc_number] => 20200291066 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => IL-2RBETA BINDING COMPOUNDS [patent_app_type] => utility [patent_app_number] => 16/884661 [patent_app_country] => US [patent_app_date] => 2020-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 111098 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16884661 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16312329 [patent_doc_number] => 20200291067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => IL-2RGAMMA BINDING COMPOUNDS [patent_app_type] => utility [patent_app_number] => 16/884726 [patent_app_country] => US [patent_app_date] => 2020-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 110917 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 170 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16884726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17242004 [patent_doc_number] => 20210361747 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => RECOMBINANT THROMBOMODULIN DOMAIN 1 FOR USE IN TREATING EYE DISEASES ASSOCIATED WITH PATHOLOGICAL OCULAR ANGIOGENESIS [patent_app_type] => utility [patent_app_number] => 16/882508 [patent_app_country] => US [patent_app_date] => 2020-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5016 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16882508 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19940485 [patent_doc_number] => 12312607 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-27 [patent_title] => AAV9 affinity agents [patent_app_type] => utility [patent_app_number] => 17/613427 [patent_app_country] => US [patent_app_date] => 2020-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 6174 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17613427 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16598060 [patent_doc_number] => 20210024591 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => TARGETING G3BP AGGREGATION TO PREVENT NEURODEGENERATION [patent_app_type] => utility [patent_app_number] => 16/881096 [patent_app_country] => US [patent_app_date] => 2020-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18186 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16881096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16762361 [patent_doc_number] => 20210107942 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => TISSUE PROTECTIVE PEPTIDES AND PEPTIDE ANALOGS FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE [patent_app_type] => utility [patent_app_number] => 16/878318 [patent_app_country] => US [patent_app_date] => 2020-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28521 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16878318 [rel_patent_id] =>[rel_patent_doc_number] =>)